GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » D&D Pharmatech Inc (XKRX:347850) » Definitions » EV-to-FCF

D&D Pharmatech (XKRX:347850) EV-to-FCF : (As of Jun. 21, 2024)


View and export this data going back to 2024. Start your Free Trial

What is D&D Pharmatech EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, D&D Pharmatech's Enterprise Value is ₩282,425 Mil. D&D Pharmatech does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate D&D Pharmatech's EV-to-FCF at this moment.

The historical rank and industry rank for D&D Pharmatech's EV-to-FCF or its related term are showing as below:

XKRX:347850' s EV-to-FCF Range Over the Past 10 Years
Min: -136.42   Med: -32.49   Max: -28.46
Current: -136.42

During the past 6 years, the highest EV-to-FCF of D&D Pharmatech was -28.46. The lowest was -136.42. And the median was -32.49.

XKRX:347850's EV-to-FCF is ranked worse than
100% of 397 companies
in the Biotechnology industry
Industry Median: 6.42 vs XKRX:347850: -136.42

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2024-06-21), D&D Pharmatech's stock price is ₩27800.00. D&D Pharmatech does not have enough years/quarters to calculate its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023. Therefore, GuruFocus does not calculate D&D Pharmatech's PE Ratio (TTM) at this moment.


D&D Pharmatech EV-to-FCF Historical Data

The historical data trend for D&D Pharmatech's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

D&D Pharmatech EV-to-FCF Chart

D&D Pharmatech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Get a 7-Day Free Trial - - - - -

D&D Pharmatech Quarterly Data
Dec22 Sep23 Dec23
EV-to-FCF - - -

Competitive Comparison of D&D Pharmatech's EV-to-FCF

For the Biotechnology subindustry, D&D Pharmatech's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


D&D Pharmatech's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, D&D Pharmatech's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where D&D Pharmatech's EV-to-FCF falls into.



D&D Pharmatech EV-to-FCF Calculation

D&D Pharmatech's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=282424.900/
=


D&D Pharmatech  (XKRX:347850) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

D&D Pharmatech's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=27800.00/
=

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


D&D Pharmatech EV-to-FCF Related Terms

Thank you for viewing the detailed overview of D&D Pharmatech's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


D&D Pharmatech (XKRX:347850) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
4th floor, 24, Pangyo-ro 255beon-gil, Bundang-gu, Gyeonggi-do, Sampyeong-dong, I&C Building, Seongnam-si, KOR
D&D Pharmatech Inc is a company that comprises of experts in the field of bio-new drug research and development and technology commercialization, including basic scientists in the pharmaceutical biofield, manufacturing quality control (CMC) experts, and clinical development and technology transfer experts. Other business areas include the development of positron emission tomography (PET) imaging biomarkers conducted by Precision Molecular Inc. a 100% subsidiary, and single-cell sequencing related to degenerative brain diseases conducted by Valted Seq, Inc. The company utilizes drug delivery technologies such as PEGylation technology, which helps extend the administration interval using PEG and various chemicals, and platform technology that converts injectable drugs into oral preparations.

D&D Pharmatech (XKRX:347850) Headlines

No Headlines